Formycon AG

Formycon AG is a biopharmaceutical company based in Germany and was founded in 1999. The company's mission, coined as The Biosimilar Experts, is to develop high-quality biopharmaceutical medicines, especially biosimilars, with a focus on treatments in ophthalmology, immunology, and other key chronic diseases. Formycon covers the entire value chain from technical development to clinical phase III and the preparation of dossiers for marketing approval. Currently, the company has four biosimilars in development, and it is also working on a COVID-19 drug FYB207. Biosimilars have promising growth prospects, as many biotech drugs are expected to lose their patent protection in the next decade. Analysts estimate that the global sales of biosimilars could exceed $15 billion by 2020 and rise to over $60 billion by 2030. The company's last investment was a €82.84M Post-IPO Equity investment on 29 January 2024, with the investment coming from the Richter Group. Formycon's expertise and dedication to providing affordable medicines to patients indicate potential success in the rapidly growing biosimilars market. With its innovative approach to biopharmaceutical development and a strong investor backing, Formycon AG seems well-positioned to capitalize on the expanding opportunities in the biopharmaceutical industry.

For more information, visit Formycon AG at Fraunhoferstr. 15, 82152 Martinsried/Planegg, Germany. Contact them via phone at +49 (0) 89 - 86 46 67 100 or email at [email protected].